Background
==========

Dengue is the most important mosquito-borne viral disease worldwide. It is often endemic across tropical and subtropical areas \[[@B1]\]. Most forms of the disease are self-limited and vary from undifferentiated fever to classic and painful dengue fever (DF); however, on rare occurrence - particularly among children - complications occur in the forms of dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) \[[@B1]\]. About 3.6 billion are at-risk of infection causing 500 million infections globally each year. Over nine million cases of DF and 18,000 deaths may occur annually \[[@B2]\].

In the context of endemicity, dengue is highly visible in the community, eliciting fear for dengue complications among mothers particularly during the dengue season. Although many developing countries recognize dengue as a public health concern, little funds are devoted to control measures. This neglect is likely related to a number of factors including the absence of specific treatment, the fact that the vaccine is still in development stage and that effective vector control interventions are too expensive for any developing countries. Above all, compared to other major infectious diseases, dengue ranks low internationally in terms of disability adjusted life years (DALYs) \[[@B3]\].

Evidence on the societal costs of the disease should help decision makers in setting priorities especially in the context of increasing health care costs and potential development of an effective vaccine. In this respect some Southeast Asian countries have produced cost of disease data at the regional and country level. Unfortunately these estimates are based on commonly underreported national surveillance data and failed to account for non-hospitalized cases or cases presenting with dengue related undifferentiated fever that occur in the community\[[@B4]-[@B7]\].

Dengue is endemic - affecting mainly children - in Cambodia (estimated population 14.4 M). Gross National Income per capita was US\$600 in 2008 <http://web.worldbank.org/>. One international study included Cambodia but with scarce specific data \[[@B7]\]. The World health Organization (WHO) also estimated the burden of dengue in Cambodia but level of evidence remained low in absence of sound data \[[@B3]\]. In the light of recent estimates of true dengue disease incidence in Cambodia, this study aimed at estimating the accurate cost of dengue and its burden using DALYs. Public expenditure and also individuals\' out-of-pocket payments were considered in the analysis. All calculations were performed for three years (2006, 2007 and 2008) in order to assess annual variations.

Methods
=======

Estimates of dengue disease incidence
-------------------------------------

We used dengue incidence and case fatality rates as provided by Vong et al who conducted an active community-based surveillance (ACS) among individuals aged 0-19 years in Kampong Cham province, Cambodia from 2006 to 2008 \[[@B8]\]. Most of the population (\~80%) lives in the southern and northwestern part of the country, mainly along the Mekong River. Kampong Cham is a central province and the most populated of Cambodia. Conditions of dengue\'s transmission are probably quiet representative of the whole country. A total of 42 villages were under active fever surveillance comprising a total study population of 14,354 participants. For groups of people aged above 20 years, it was assumed that incidences were constant. Since the vast majority of dengue cases in Cambodia occurred before age 20, assumptions made for adults appeared reasonable \[[@B9]\].

Cost of illness
---------------

In a recent review, Tarricone *et al*suggested that cost of illness studies (COI) have to measure as accurately as possible \"the true cost to society\" to usefully inform decision makers. To achieve this goal, COI must include estimates of costs components and identification of subjects that bear the costs \[[@B10]\]. We used the methods of Tarricon*e et al*to estimate the cost of dengue in Cambodia. Medical resources include direct treatment costs (hospital costs, out patients costs, medication) and direct control costs (vector control programs, prophylaxis) \[[@B11]\]. Productive costs or indirect costs are costs related to morbidity and premature mortality \[[@B10],[@B11]\]. We used disease burden incidence data calculated annually for the years 2006-8. To estimate costs, a bottom-up approach was chosen. We used dengue incidence and case fatality rates as provided by Vong et al. Results from the ACS suggested that health-seeking behavior changed from year to year. While 95% of dengue patients sought care in 2006, only about 50% and less than 40% sought care in 2007 and 2008 respectively \[[@B8]\]. Incidence rates and health seeking behaviors are displayed in table [1](#T1){ref-type="table"}. For sensitivity analyses, we held health-seeking behaviors observed in 2006 for 2007 and 2008. We assumed that 2007 large epidemic could have had an impact on \"usual\" health care consumption. The share of private providers (private clinics and pharmacy) was consistent with the results of the Cambodian Health Survey \[[@B12]\]. Assumptions on costs distribution among government, families (Out-of-pocket payments) and other organizations (mainly Non Governmental Organizations (NGOs)) are displayed on Table [2](#T2){ref-type="table"}. Public hospitals and health centers receive public subsidies that represent 50% of the total expenditure. In addition, another 20% of total costs are born by Health equity funds or other mechanisms of health insurance. Out-of-pocket payments account for the remaining 30%. Private clinics and pharmacies are fully financed by user fees. Costs figures were derived from specific studies carried out on Dengue and access to heath care in Cambodia \[[@B13]-[@B15]\]. It was assumed that only one provider delivered health care although qualitative studies suggest that several health services could be sought in some cases \[[@B16]\]. To estimate productive costs, a Human Capital Approach (HCA) was chosen in absence of sound data of the work market in Cambodia. The World Bank estimated average annual income of US\$600. For each dengue fever episode, an average of 5 workdays lost was taken, which was consistent with previous studies \[[@B17]\]. It was assumed that this loss was equal for adults and children since at least one parent has to forgo his/her activity to care his/her sick child. In prevalence-based studies, lost expected earnings caused by premature mortality are assigned to the year of death \[[@B10]\]. Thus, future losses due to premature mortality were estimated using life expectancy at age of death with a starting age of work set at 15 years. A discount rate of 3% per year was applied in the baseline case and a flat rate was used for sensitivity analyses.

###### 

Estimated number of total cases, hospitalized cases and fatal cases of dengue disease in Cambodia, incidence by group of age and health seeking behavior by year

                                     2006     2007      2008
  ---------------------------------- -------- --------- ---------
  Estimated No. cases                76,933   404,165   121,007
  Estimated No. hospitalized cases   31,983   42,704    3,129
  Estimated No. fatal cases          153      407       72
  Incidence rate                                        
   \<5 years                         16.0     79.2      15.5
   5-9 years                         15.8     83.7      24.4
   10-14 years                       8.9      46.2      17.2
   15-19 years                       1.1      15.2      6.8
   \>20 years                        0.5\*    1.5\*     1.0\*
  Health seeking behavior                               
   % who seek care                   93       50        37
   % public hospital                 42       11        3
   % private clinic                  48       31        28
   % health center                   2        4         1
   % pharmacy                        1        5         5

\* Expert estimates

###### 

Unit costs and their distribution

  ----------------------------------------------------------------------------------------------
                           Unit cost\   Distribution\   Reference                   
                           (\$US)       (%)                                         
  ------------------------ ------------ --------------- --------------- ----------- ------------
                                        **Public**      **User fees**   **Other**   

                                                                                    

  Direct costs                                                                      

   Direct medical costs                                                             

    Public hospital        67           50              30              20          (13-15)

    Private clinic         20                           100                         

    Health center          33           50              30              20          

    Pharmacy               5                            100                         

   Direct control costs                                                             

    Larviciding campaign   500,000      100                                         \(32\)

  Productive costs                                                                  

    Morbidity              8                            100                         World Bank

    Mortality              600\*                        100                         
  ----------------------------------------------------------------------------------------------

\*With an annual discount rate of 3%

Burden of disease
-----------------

DALYs were calculated using Murray\'s formula \[[@B18]\] but also taking into account recent remarks aiming at improving comparability and transferability of results \[[@B19]\]. Therefore, local life expectancy was used instead of standard life expectancy. Thus, DALYs are estimated by summing years of life lost (YLLs) and years of life lived with disability (YLDs).

$$YLLs\left\lbrack {r,K,\beta} \right\rbrack = \frac{KCe^{ra}}{\left( {r + \beta} \right)^{2}}\left\{ {e^{- {({r + \beta})}{({L + a})}}\left\lbrack {- \left( {r + \beta} \right)\left( {L + a} \right) - 1} \right\rbrack - e^{- {({r + \beta})}a}\left\lbrack {- (r + \beta)a - 1} \right\rbrack} \right\} + \frac{1 - K}{r}\left( {1 - e^{- rL}} \right)$$

*Where*: *K*= age weighting factor; *C*= constant; *r*= discount rate; *a*= age of death; *β*= parameter from the age weighing function; *L*= expectation of life at age *a*.

$$YLDs\left\lbrack {r,K,\beta} \right\rbrack = D\left\{ \frac{KCe^{ra}}{\left( {r + \beta} \right)^{2}}\left\{ {e^{- {({r + \beta})}{({L + a})}}\left\lbrack {- \left( {r + \beta} \right)\left( {L + a} \right) - 1} \right\rbrack - e^{- {({r + \beta})}a}\left\lbrack {- (r + \beta)a - 1} \right\rbrack} \right\} + \frac{1 - K}{r}\left( {1 - e^{- rL}} \right) \right\}$$

We used the base case recommended by Murray and Lopez with *C*= 0.1658, *r*= 0.03, *K*= 1 and *β*= 0.04 \[[@B20]\]. Other factors were calculated for 17 groups of age in 5 year increments (\<5 years, 5-9 years and so on until \>80 years). Specific incidence rate of dengue, hospitalization and mortality were used for the first four groups of age (from \<5 to 15-19 years) as provided by Vong et al \[[@B8]\]. As for previous similar studies carried out in other countries, a disability weight of 0.81 \[[@B4],[@B21],[@B22]\] and a duration of disability of 5 days were chosen \[[@B17]\].

Results
=======

Cost of illness
---------------

Overall annual dengue costs ranged from US\$3,327,284 in 2008 up to US\$14,429,513 in 2007 with 2006 showing comparable amounts to 2008 (Table [3](#T3){ref-type="table"}). In absence of a discount rate applied to future losses due to premature mortality, total costs doubled. On average the cost per dengue case was US\$75 in 2006 and dropped to US\$36 in 2007 and US\$27 in 2008. Direct medical cost per case was \$38 in 2006, \$15 in 2007 and US\$8 in 2008. When considering cases that sought care in both private and public sectors, these numbers rose to US\$41 in 2006, US\$29 in 2007 and US\$21 in 2008 per case. Patients and their families support the highest share of costs with 65%, 80% and 80% of the total cost for 2006, 2007 and 2008 respectively (Fig. [1](#F1){ref-type="fig"}). When considering only direct medical costs, out-of-pocket payments represented 48%, 60% and 82% of the total for 2006, 2007 and 2008 respectively (Fig. [2](#F2){ref-type="fig"}). A sensitivity analysis was performed estimating costs in 2007 and 2008 with health seeking behaviors of 2006. Thus, costs in 2007 would be multiplied by 1.7 and costs of 2008 by 2.1.

###### 

Costs by year (\$US)

                                   2006          2007           2008
  -------------------------------- ------------- -------------- -------------
  Total costs                      5,771,079     14,429,513     3,327,284
   Direct costs                    3,437,570     6,432,840      1,463,189
    Medical costs                  2,937,570     5,932,840      963,189
     Public hospitals              2,132,224     2,846,950      208,633
     Private clinics               743,397       2,470,746      688,489
     Health centers                57,628        508,384        34,772
     Pharmacies                    4,322         106,761        31,295
    Control costs                  500,000       500,000        500,000
   Productive costs                2,333,509     7,996,673      1,864,095
    Morbidity                      632,325       3,321,906      994,579
    Mortality (3% discount rate)   1,701,183     4,674,767      869,516
    (Mortality (no discount))      (4,592,640)   (12,354,240)   (2,197,920)

![**Proportion of total costs born by families, government and other stakeholders**.](1471-2458-10-521-1){#F1}

![**Proportion of direct medical costs born by families, government and other stakeholders**.](1471-2458-10-521-2){#F2}

Burden of disease
-----------------

Estimated DALY rates per 100,000 inhabitants ranged from 24.3 in 2008 to 116.6 in 2007 with 2006 in between at 40.0 (Table [4](#T4){ref-type="table"}). The share due to premature mortality (Years of life lost/total DALYs) was 91%, 83% and 70% for 2006, 2007 and 2008 respectively.

###### 

Estimated DALYs by year

                                     2006    2007     2008
  ---------------------------------- ------- -------- -------
  Estimated total DALYs              5,603   16,330   3,397
   Estimated YLLs                    5,101   13,583   2,391
   Estimated YDLs                    502     2,747    1,006
  Estimated DALYs rate/10^5^inhab.   40.0    116.6    24.3

DALYs: diability adjusted life years

YLLs: years of life lost

YDLs: years of life lived with disability

Discussion
==========

On costs
--------

Our analyses confirmed the high societal burden of dengue in Cambodia whose total costs represented between 0.03 and 0.17% of Cambodia\'s Gross Domestic Product. We feel that this analysis is a more accurate estimate of Cambodia\'s cost of illness due to dengue fever. These costs calculations were based upon robust estimates provided by the ACS of a large population. Unlike previous estimates, proportions of both hospitalized and ambulatory cases were accounted for \[[@B7]\]. Moreover, the study provided a longitudinal perspective of the burden of dengue through estimates from three years with differing epidemiological patterns. Indeed, the incidence data encompassed a regular seasonal epidemic year (2006), a large scale epidemic year (2007) and Year 2008 - a year following a major epidemic. This situation has been observed to be associated with a year of milder clinical presentation and lower incidence of dengue fever \[[@B23]\].

Nevertheless, these numbers still probably represent an underestimation of the real costs caused by endemic dengue. Mothers are well aware of the risks of potential severity during the dengue season. There is a local name for dengue \"krun chheam\" which translates into \"hemorrhagic fever\" in Khmer language. As such, during the rainy season fearing hemorrhagic dengue, it is thought that more mothers would seek hospital admission when their children present with febrile illnesses than that they would during the low dengue season. This phenomenon is likely to saturate hospitals capacities and to lower global health care quality because of an overwhelmed staff coping with commonly ill-equipped facilities. As defined by health economists, opportunity costs would occur when treatments for patients suffering from other diseases have to be postponed because of the dengue outbreak \[[@B11]\]. Our results underlined the importance of health seeking behavior on costs. The sensitivity analysis showed that changes in heath seeking behavior in 2007 decreased the medical costs.

COI aim at assessing the economic burden of a given disease to society. Since introduction of these studies, their utility in the decision-making process has often been disputed \[[@B10]\]. Some authors argue that COI merely identify diseases for which large amount of resources are already allocated \[[@B24]\]. COI could also fail in identifying diseases amenable by medical treatment or prevention \[[@B25]\]. Finally it is difficult to compare COI between countries of different health care capacity and access of individuals to adequate health care. Although incidence of dengue may be among the highest, COI may be proportionately lower compared with more developed neighboring countries as ill-equipped public and private hospitals would spend less on symptomatic treatment of dengue. Indeed, our results indicated that small amounts were devoted to dengue in Cambodia compared to other countries with an average cost per case around US\$50 \[[@B7]\]. More importantly, despites recent effort by the Cambodian government to introduce safety nets (insurance) or health equity funds in hospitals, the burden of this cost is disproportionately born by the patients and their relatives. In 1997, Cambodia introduced user fees in order to increase hospital revenue, to limit under-the-table payments and eventually improve the quality of care \[[@B26],[@B27]\]. It was thought that the system could improve financial sustainability and increase heath services utilization, as a consequence of higher quality health services \[[@B28]\]. Hitherto, results from early studies suggest that overall health care utilization increased following user fees introduction \[[@B29]\]. However, utilization of the poorer members of the community is not well documented. In addition nearly half of district hospitals were not covered by equity funds in 2006 \[[@B26]\]. Fee-exemption rates in Cambodia are known to be relatively low compared to other developing countries \[[@B26]\]. Since a significant proportion of Cambodians have no access or cannot afford private health care, many families forgo healthcare. This would be supported by recent findings that suggested a lower hospitalization rate for dengue in Cambodia\'s poorest households \[[@B14]\]. For the poorest, healthcare access or hospital costs remained an insurmountable issue \[[@B24]\] because loans and high interest rates can impoverish them for many years \[[@B14]\].

On DALYs
--------

Our results are consistent with previous studies. Sheppard *et al.*reported a DALY rate of 42 DALYs/100,000 in South East Asia \[[@B17]\] and the WHO estimated 54 DALYs/100,000 caused by dengue in Cambodia in 2004. However, Sheppard *et al.*found that 52% of DALYs were due to premature mortality whereas our results showed a higher share. Cambodia has a very young population with about 50% of the population under 20 years. Since duration of disability is very short and the vast majority of deaths occurred in the 0-20 age group, our estimate is probably more accurate. Some authors reproach age weighting in DALYs calculation to give more value to young adults than to other groups of age \[[@B30]\]. In the Cambodian demographic context, such assumption tends to underestimate the true burden of dengue. Compared to other DALYs estimates provided by the WHO, the burden of dengue appears similar to those of Japanese encephalitis (54 DALYs/100,000), trachoma (69 DALYs/100,000) or even malaria (143 DALYs/100,000). Regional comparisons suggest a burden equivalent in Thailand (60 DALYs/100,000) and Laos (93 DALYs/100,000).

Limitations
-----------

As mentioned previously, opportunity costs were not taken into account and are likely to have an important impact on overall costs. Unfortunately, such data were not available and further studies are needed to document these costs. Incidence rates for groups of age above 20 years old were based on assumptions. Average income estimates were based on macroeconomic indicators since accurate data on both salaries and unemployment rate were not available. Median income is likely to be inferior to mean income in Cambodia because of a minority of people with very high incomes. Moreover, all estimates are subject to inaccuracy since informal work represents the majority of employment in Cambodia \[[@B31]\]. However, conservative values were taken on purpose to avoid any overestimation (1 dengue case per 1000 pop. on average).

Implications for health policy
------------------------------

The question is to determine whether COI and DALYs are helpful in prioritizing resources allocation. At first glance, burden of dengue could appear as an issue little importance in Cambodia. DALYs caused by tuberculosis (1,712 DALYs/100,000) or meningitis (356 DALYs/100,000) are by far more considerable (WHO 2004 estimates). However, dengue strikes primarily children in Cambodia, resulting in a lesser impact on DALYs calculation. Regardless of costs underestimation, the share born by families clearly gives an indication of the true burden of dengue for Cambodians. Should a dengue vaccine be highly cost effective, its introduction in Cambodia would provide great benefits to the population \[[@B17]\] in terms of reduced incurrence of debt \[[@B14]\].

Conclusions
===========

To conclude, decision makers should take into account dengue costs particularly among the poor and the psychological stress caused by the disease in the population (assessed by their willingness to pay) when balancing the benefits of introducing a potentially effective dengue vaccine. In Cambodia, dengue is a health issue as much as an equity concern. This report establishes a methodological approach that uses more accurate estimates of dengue disease burden to suggest the importance of using cost indicators when considering the introduction of a dengue vaccine in Cambodia. Specific studies should also document the efficiency of other interventions. Previous studies performed in Cambodia reported contradictive results \[[@B9],[@B32]\].
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